<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="364697">
  <stage>Registered</stage>
  <submitdate>30/07/2013</submitdate>
  <approvaldate>2/08/2013</approvaldate>
  <actrnumber>ACTRN12613000856718</actrnumber>
  <trial_identification>
    <studytitle>Metformin for Mind and Metabolism</studytitle>
    <scientifictitle>Metformin for Mind and Metabolism: The effect of metformin 2000mg/day on mood and cognition in adults with treatment resistant depression and abdominal obesity: a pilot randomized placebo controlled trial over 12 weeks.</scientifictitle>
    <utrn />
    <trialacronym>The MMM study</trialacronym>
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Depression</healthcondition>
    <healthcondition>Abdominal Obesity</healthcondition>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Depression</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Diet and Nutrition</conditioncode1>
      <conditioncode2>Obesity</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Metformin 2 x 500mg oral tablets twice daily for 12 weeks (total daily dose 2000mg). Adherence will be monitored by counting drug returns on a monthly basis.</interventions>
    <comparator>Placebo (gelatine capsule filled with lactose powder) oral capsule taken twice daily for 12 weeks</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>severity of depression as assessed using the MADRS (Montgomery Asperg Depression Rating Scale)</outcome>
      <timepoint>12 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>change in cognition as measured by CogState (computer based cognitive testing)</outcome>
      <timepoint>12 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>change in weight as determined by using calibrated digital scales</outcome>
      <timepoint>12 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>adults aged 18-65
ongoing symptoms of depression (MADRS&gt;10) despite at least 8 weeks on a stable dose of an antidepressant
adbominal obesity (waist circumference &gt;88cm for women or 102cm for men)</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>renal impairment (eGFR&lt;60)
suicidal
psychotic disorders
diabetes mellitus
allergy to metformin, lactose or other component of metformin or placebo formulations</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1>True</masking1>
    <masking2>True</masking2>
    <masking3>True</masking3>
    <masking4>True</masking4>
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>2/09/2013</anticipatedstartdate>
    <actualstartdate>16/06/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>30</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>The Alfred Hospital</primarysponsorname>
    <primarysponsoraddress>Commercial Rd
Prahran
Melbourne VIC
3181</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Preston and Loui Geduld Charitable Trust</fundingname>
      <fundingaddress>Equity Trustees
Level 2, 575 Bourke St
Melbourne VIC 3000</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>None</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Metformin is a medication originally derived from French Lilac which has been used to treat diabetes for over 50 years. The aim of this study is to see whether metformin can improve mood and memory in people who have depression and obesity. We will recruit 30 adults who feel depressed despite currently taking an antidepressant medication and who also have a large waist measurement (more than 88cm for women and 102cm for men). The study will last for 12 weeks. Participants will be randomized to either metformin 1000mg twice per day with food or placebo. At the beginning and the end of the study mood will be rated by self-report and by the doctors impression. Memory will be measured using a series of computer based tests, similar to playing simple computer games. The hope is that metformin will help obese adults with depression by reducing levels of the hormone insulin as well as markers of inflammation, within the brain, thereby improving mood.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>The Alfred Hospital Ethics Committee</ethicname>
      <ethicaddress>The Alfred Hospital
Commercial Rd
Prahran VIC
3181</ethicaddress>
      <ethicapprovaldate>20/09/2013</ethicapprovaldate>
      <hrec>126/13</hrec>
      <ethicsubmitdate>31/07/2013</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Monash University Human Research Ethics Committee </ethicname>
      <ethicaddress />
      <ethicapprovaldate>30/10/2013</ethicapprovaldate>
      <hrec>CF13/3101 - 2013001644</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Roisin Worsley</name>
      <address>Monash Alfred Psychiatry Research Centre
Level 4
607 St Kilda Rd
Melbourne VIC 3004</address>
      <phone>+61 3 9076 6564</phone>
      <fax />
      <email>roisin.worsley@monash.edu</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Roisin Worsley</name>
      <address>Monash Alfred Psychiatry Research Centre
Level 4
607 St Kilda Rd
Melbourne VIC 3004</address>
      <phone>+61 3 9076 6564</phone>
      <fax />
      <email>roisin.worsley@monash.edu</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Roisin Worsley</name>
      <address>Monash Alfred Psychiatry Research Centre
Level 4
607 St Kilda Rd
Melbourne VIC 3004</address>
      <phone>+61 3 9076 6564</phone>
      <fax />
      <email>roisin.worsley@monash.edu</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>